Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry (Q34065405)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry |
scientific article |
Statements
1 reference
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry (English)
1 reference
F Tubach
1 reference
D Salmon
1 reference
Y Allanore
1 reference
P Goupille
1 reference
M Bréban
1 reference
B Pallot-Prades
1 reference
S Pouplin
1 reference
A Sacchi
1 reference
R M Chichemanian
1 reference
D Emilie
1 reference
M Lemann
1 reference
O Lortholary
1 reference
X Mariette
1 reference
Research Axed on Tolerance of Biotherapies Group
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference